Technology ID
E-470-2013-0

Rabies Vaccine for the Oral Immunization of Domesticated Animals, Wildlife and Feral Animals

Linked ID
TAB-2785
Inventors
Bernhard Dietzschold (Thomas Jefferson University)
Charles Rupprecht (CDC)
D. Craig Hooper (Thomas Jefferson University)
Matthias Schnell (Thomas Jefferson University)
Lead Inventors
Bernhard Dietzschold (Thomas Jefferson University)
Co-Inventors
Charles Rupprecht (CDC)
D. Craig Hooper (Thomas Jefferson University)
Matthias Schnell (Thomas Jefferson University)
Development Stages
Pre-clinical (in vivo)
Development Status
  • In vitro data available
  • In vivo data available (animal)
Therapeutic Areas
Infectious Disease
ICs
CDC
Commercial Applications
  • Wildlife and humane shelter rabies prevention and control programs
  • Improved rabies vaccines for pets and livestock
  • Humane, targeted approach to elimination of rabies reservoirs in feral animal populations
This invention, developed by the CDC and collaborators, entails a live, attenuated recombinant rabies virus vaccine that can elicit an effective anti-rabies immune response in animal recipients. Inoculation with a live, attenuated, rabies virus allows for the optimized production of immunity in the absence of pathogenicity. Oral administration of rabies vaccines is often a preferred route of vaccine delivery because it is most effective in wildlife. Unfortunately, availability of an oral vaccine for canines has been a significant hurdle to date.

This vaccine technology could be used for immunization of stray dogs by an oral route. In developing nations, more than 90% of human exposure events and 99% of human deaths due to rabies are caused by rabid dogs. Using this vaccine with a broadly implemented oral vaccination strategy provides a promising opportunity for reducing transmission of rabies between stray dogs and, thereby, increasing protection for people.
Competitive Advantages
  • Safe and effective
  • Oral immunization is the most practical and efficient method of rabies vaccination of wildlife and feral animals
  • Vaccine has demonstrated protection in vivo
  • Recombinant, non-neuroinvasive virus expressing a neuroinvasive glycoprotein and/or pro-apoptotis gene safely induces a robust and desirable immunological response

Request More Info

Licensing Contact